Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2004-004545-18-BE
EUCTR2004-004545-18-BE
Active, not recruiting
Not Applicable

Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in patients with chronic ischemic cardiomyopathy. - NA

CHU Sart Tilman0 sites24 target enrollmentDecember 12, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsNeorecormon 5000Neupogen 30 Mio UNeupogen 48 Mio U

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
CHU Sart Tilman
Enrollment
24
Status
Active, not recruiting
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 12, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
CHU Sart Tilman

Eligibility Criteria

Inclusion Criteria

  • •\- Stable chronic ischemic cardiopathy
  • •\- Optimal drug treatment
  • •\- No possible cardiac surgery or angioplasty
  • •\- NYHA class II\-IV
  • •\- Left ventricular ejection fraction \<40%
  • •\- Collateral circulation and/or hibernating myocardium
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- Inclusion criteria not fully met
  • •\- Previous neoplasia (except in situ cervical cancer or non\-melanoma skin cancer)
  • •\- HIV, HBsAg or HC positive status
  • •\- Hematological condition potentially impairing response to haematopoietic growth factors
  • •\- Active infection or inflammatory disorder
  • •\- Uncontrolled hypertension
  • •\- Allergy to G\-CSF or EPO
  • •\- Hb \>16 g/dl
  • •\- Blood transfusion dependance

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)Stem Cell TransplantationVentricular Dysfunction, Left
NCT00768066University of Miami65
Recruiting
Phase 1
Clinical trial to study the safety and efficacy of stem cell therapy in patients with severe ventricular dysfunctio
CTRI/2009/091/000590Frontier Lifeline PvtLtd90
Recruiting
Not Applicable
Quantifying New Heart Muscle CellsTetralogy of Fallot With Pulmonary StenosisHeart Failure
NCT06587165Weill Medical College of Cornell University30
Completed
Phase 1
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)Stem Cell Transplantation
NCT01087996University of Miami31
Completed
Phase 1
PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)Non-ischemic Dilated Cardiomyopathy
NCT01392625Joshua M Hare37